Scott E. Eggener to Neoplasms, Germ Cell and Embryonal
This is a "connection" page, showing publications Scott E. Eggener has written about Neoplasms, Germ Cell and Embryonal.
Connection Strength
7.233
-
National management trends in clinical stage IIA nonseminomatous germ cell tumor (NSGCT) and opportunities to avoid dual therapy. Urol Oncol. 2020 08; 38(8):687.e13-687.e18.
Score: 0.713
-
Indications, evolving technique, and early outcomes with robotic retroperitoneal lymph node dissection. Curr Opin Urol. 2018 09; 28(5):461-468.
Score: 0.637
-
Clinical and Radiographic Predictors of Great Vessel Resection or Reconstruction During Retroperitoneal Lymph Node Dissection for Testicular Cancer. Urology. 2019 01; 123:186-190.
Score: 0.637
-
Late Relapse of Nonseminomatous Germ Cell Tumor 24 Years Later. Urology. 2018 Dec; 122:16-18.
Score: 0.636
-
Management trends for men with early-stage nonseminomatous germ cell tumors of the testicle: An analysis of the National Cancer Database. Cancer. 2017 01 01; 123(2):245-252.
Score: 0.556
-
Safety and Early Oncologic Effectiveness of Primary Robotic Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer. Eur Urol. 2017 03; 71(3):476-482.
Score: 0.544
-
Management of Low-Stage Testicular Seminoma. Urol Clin North Am. 2015 Aug; 42(3):287-98.
Score: 0.509
-
Critical evaluation of modified templates and current trends in retroperitoneal lymph node dissection. Curr Urol Rep. 2013 Oct; 14(5):511-7.
Score: 0.453
-
Retroperitoneal lymph node dissection: reassessment of modified templates. BJU Int. 2009 Nov; 104(9 Pt B):1369-75.
Score: 0.345
-
The evolution, controversies, and potential pitfalls of modified retroperitoneal lymph node dissection templates. World J Urol. 2009 Aug; 27(4):477-83.
Score: 0.332
-
Incidence of disease outside modified retroperitoneal lymph node dissection templates in clinical stage I or IIA nonseminomatous germ cell testicular cancer. J Urol. 2007 Mar; 177(3):937-42; discussion 942-3.
Score: 0.287
-
Risk Factors for Relapse in Nonseminomatous Testicular Cancer After Postchemotherapy Retroperitoneal Lymph Node Dissection With Viable Residual Cancer. J Clin Oncol. 2023 Dec 01; 41(34):5296-5305.
Score: 0.225
-
Surgery in Early Metastatic Seminoma: A Phase II Trial of Retroperitoneal Lymph Node Dissection for Testicular Seminoma With Limited Retroperitoneal Lymphadenopathy. J Clin Oncol. 2023 06 01; 41(16):3009-3018.
Score: 0.218
-
Risk of residual cancer after complete response following first-line chemotherapy in men with metastatic non-seminomatous germ cell tumour and International Germ Cell Cancer Cooperative Group intermediate/poor prognosis: A multi-institutional retrospective cohort study. Eur J Cancer. 2023 03; 182:144-154.
Score: 0.216
-
Robotic post-chemotherapy retroperitoneal lymph node dissection for testicular cancer: A multicenter collaborative study. Urol Oncol. 2023 02; 41(2):111.e7-111.e14.
Score: 0.213
-
Minimally invasive retroperitoneal lymph node dissection for men with testis cancer: a retrospective cohort study of safety and feasibility. World J Urol. 2022 Jun; 40(6):1505-1512.
Score: 0.203
-
Impact of Non-guideline-directed Care on Quality of Life in Testicular Cancer Survivors. Eur Urol Focus. 2021 Sep; 7(5):1137-1142.
Score: 0.185
-
Nationwide Patterns of Care for Stage II Nonseminomatous Germ Cell Tumor of the Testicle. Eur Urol Oncol. 2020 04; 3(2):198-206.
Score: 0.169
-
Clinical outcome and predictors of survival in late relapse of germ cell tumor. J Clin Oncol. 2008 Dec 01; 26(34):5524-9.
Score: 0.080
-
Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection. J Clin Oncol. 2007 Oct 01; 25(28):4365-9.
Score: 0.075